Please login to the form below

Not currently logged in
Email:
Password:

erenumab

This page shows the latest erenumab news and features for those working in and with pharma, biotech and healthcare.

New efficacy data boosts Aimovig’s migraine market lead

New efficacy data boosts Aimovig’s migraine market lead

The results from the STRIVE trial are good news for Novartis and its co-marketer Amgen, who have established Aimovig (erenumab) as the leader in the new class of CGRP inhibitor

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics